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Abstract
Background: Invasive fungal infection (IFI) is associated with high morbidity and high mortality in hematopoietic
stem cell transplantation (HSCT) patientsThe purpose of this study was to assess the characteristics and outcomes
of HSCT patients with IFIs who are undergoing MV at a single institution in Taiwan.
Methods: We performed an observational retrospective analysis of IFIs in HSCT patients undergoing mechanical
ventilation (MV) in an intensive care unit (ICU) from the year 2000 to 2009. The characteristics of these HSCT
patients and risk factors related to IFIs were evaluated. The status of discharge, length of ICU stay, date of death
and cause of death were also recorded.
Results: There were 326 HSCT patients at the Linkou Chang-Gung Memorial Hospital (Taipei, Taiwan) during the
study period. Sixty of these patients (18%) were transferred to the ICU and placed on mechanical ventilators. A
total of 20 of these 60 patients (33%) had IFIs. Multivariate analysis indicated that independent risk factors for IFI
were admission to an ICU more than 40 days after HSCT, graft versus host disease (GVHD), and high dose
corticosteroid (p < 0.01 for all). The overall ICU mortality rate was 88% (53 of 60 patients), and was not significantly
different for patients with IFIs (85%) and those without IFIs (90%, p = 0.676).
Conclusion: There was a high incidence of IFIs in HSCT patients requiring MV in the ICU in our study cohort. The
independent risk factors for IFI are ICU admission more than 40 days after HSCT, GVHD, and use of high-dose
corticosteroid.
Keywords: Invasive fungal infection (IFI), Hematopoietic stem cell transplantation (HSCT), Intensive care unit (ICU),
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Background
Hematopoietic stem cell transplantation (HSCT) is a
treatment option for malignant and non-malignant
hematological disorders such as leukemia, lymphoma,
myelodysplastic syndrome, and aplastic anemia. Despite
improvements in HSCT, its widespread adoption has
been limited due to the high rate of severe complications
associated with the toxicity of the conditioning regimen,
immunosuppression, and graft-versus-host disease
(GVHD) [1]. These complications are commonly related
to the underlying illness and often require admission to
an intensive care unit (ICU) [2,3]. More than 60% of
HSCT recipients are admitted to an ICU, and these
patients have very poor prognosis [4,5]. Although the
mortality rate of HSCT recipients admitted to the ICU
has declined in the past two decades, it still exceeds 80%
for patients on mechanical ventilation (MV) [5].
Invasive fungal infections (IFIs) are increasingly diag-
nosed in critically ill HSCT patients. The main risk factors
for an IFI are advanced age, use of an unmatched donor,
neutropenia, acute GVHD, underlying disease, corticoster-
oid therapy, and duration of fungemia [6]. Other risk fac-
tors for serious fungal infection are the nature of the
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any medium, provided the original work is properly cited.critical illness, use of immunosuppressive therapy, pre-
sence of neutropenia, use of multiple broad-spectrum anti-
biotics, use of total parenteral nutrition, and presence of
an indwelling catheter [6]. Despite advances in HSCT pro-
cedures, improved prophylactic antifungal agents, and
better ICU care, mortality and morbidity remain major
concerns for HSCT patients with IFIs [7].
HSCT recipients with respiratory failure who need
MV have increased risk of transplant-related morbidity
and mortality, but few reports have examined the asso-
ciation of IFI and in these patients. The purpose of this
study was to assess the characteristics and outcomes of
HSCT patients with IFIs who are undergoing MV at a
single institution in Taiwan.
Methods
Patient information and data collection
A total of 326 adult patients underwent HSCT in Linkou
Chang-Gung Memorial Hospital (Taipei, Taiwan) between
January 2000 and December 2009. Four patients whose
families declined ICU admission and two patients who
died before ICU admission were excluded. For patients
with multiple ICU admissions during the study period,
only the first admission episode was analyzed. Ultimately,
a total of 60 HSCT patients who were undergoing
mechanical ventilation (MV) and admitted to the medical
ICU during the study period were enrolled. The Institu-
tional Review Board and the Chang Gung Medical Foun-
dation (IRB no. 99-2134B) approved this study. Consent
was waived due to the retrospective nature of the study.
The medical records of 60 patients were retrospectively
reviewed. On the first day of ICU admission, we recorded
patient age, gender, underlying disease, date and type of
transplantation (autologous or allogeneic), stem cell
source (bone marrow or peripheral blood stem cells),
laboratory analyses, hemodynamic status, renal and hepa-
tic function, episodes of concurrent GVHD, cytomegalo-
virus (CMV) infection, and corticosteroid use. The acute
physiology and chronic health evaluation (APACHE) II
score and the sequential organ failure assessment (SOFA)
[8] score were calculated for each patient within the first
24 h of ICU admission.
For patients with IFIs, we recorded the clinical charac-
teristics, cytological or histological results, mean duration
of diagnosis after ICU admission, and treatment. We also
evaluated the stem cell source, donor type, presence of
acute or chronic GVHD, CMV infection, neutrophil
count, bacteremia, and corticosteroid use in all patients.
The status of discharge, length of ICU stay, date of death,
and cause of death were also recorded.
Definitions
Each IFI patient was classified as having “proven IFI”,
“probable IFI”,o r“possible IFI” based on criteria of the
European Organization for Research and Treatment of
Cancer/Mycoses Study Group (EORTC/MSG) [9]. In
brief, proven IFI was diagnosed by serologic analysis,
microscopic analysis, and culture; probable IFI was diag-
nosed by host, clinical criteria, and mycological criteria;
and possible IFI was diagnosed by the same criteria as
probable IFI, except that mycological criteria were not
used. The day on which the second positive diagnostic test
was performed was defined as the day of IFI diagnosis.
When an IFI was diagnosed by surgical lung biopsy or
trans-bronchial lung biopsy, the day of diagnosis was
defined as the day of the first clinical suspicion of IFI. IFI
was defined as an early infection if it occurred within 40
days after HSCT, and was otherwise defined as a late
infection. Previous studies have used this cutoff date as an
indication of the immediate post-engraftment period [10].
Acute GVHD was defined as GVHD that occurred
within 100 days after myeloablative chemotherapy [11].
T h es e v e r i t yo fa c u t eG V H Di nt h et h r e em a i nt a r g e t
organs (skin, liver, gastrointestinal tract) was assigned
stage 1 to 4 based on accepted criteria [12]. Chronic
GVHD is determined by a 0- to 3-point score (none,
mild, moderate, severe) that reflects the clinical effect in
various organs including skin, liver, eyes, mouth, respira-
tory tract, and esophagus [13].
Cytomegalovirus (CMV) infection was diagnosed by
positive culture and characteristic pathological findings in
specimens from a surgical lung biopsy or bronchoalveolar
lavage. Neutropenia was diagnosed as a neutrophil count
less than 500 cells/mL for more than 10 days. Concurrent
bacteremia was diagnosed if bacteria were isolated from
blood culture within one week of the diagnosis of IFI.
High dose corticosteroid use was defined as more than
0.3 mg/kg/day prednisolone for more than three weeks.
Statistical analysis
Data were analyzed with SPSS 13.0 (SPSS Inc. Chicago, II,
USA). The characteristics of with and without IFIs were
compared by a Chi-square test for categorical variables
and by an independent t-test for continuous variables. If
the cells of a 2 × 2 table had an expected count less than
five, Fisher’s Exact Test was used. Risk factors for IFI were
initially assessed by univariate analysis. Variables that were
statistically significant (p < 0.05) in the univariate analysis
w e r ei n c l u d e di nam u l t i v a r i a t ea n a l y s i sb yam u l t i p l e
logistic regression based on the backward elimination of
data. All statistical tests were two-tailed and a p-value less
than 0.05 was considered statistically significant.
Results
A total of 326 patients underwent HSCT at our institu-
tion during the study period, and 66 of these patients
had respiratory failure before ICU admission that neces-
sitated MV. Six of those patients were excluded because
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Table 1 shows the baseline characteristics of the 60
enrolled patients.
A total of 20 of these 60 HSCT patients undergoing
MV had IFIs (33%). Table 2 shows the basic characteris-
tics of patients with and without IFIs. Five of the 20
patients diagnosed with IFIs were diagnosed within 30
days after HSCT, four patients were diagnosed between
30 and 100 days after HSCT, and 11 patients were diag-
nosed more than 100 days after HSCT. Patients with IFIs
were significantly younger than those without IFIs (30 vs.
37 yrs., p = 0.024). IFI patients were significantly more
likely to be diagnosed with GVHD and to have received
high dose corticosteroid therapy (94% vs. 52%, p = 0.003
and 65% vs. 25%, p = 0.003, respectively). In addition, the
APACHE II and SOFA scores were significantly lower in
patients with IFIs (21.6 vs. 26.7, p = 0.014 and 10.5 vs.
12.8, p = 0.02, respectively). The overall ICU mortality
rate was 88% (53/60), and was not significantly different
between the two groups (85% vs. 90%).
Table 3 shows the results of our multivariate analysis
of variables associated with IFIs. The results indicate
that ICU admission more than 40 days after HSCT,
diagnosis of GVHD, and use of high dose corticosteroid
were significantly and independently associated with
IFIs.
The average time of IFI diagnosis was four days after
ICU admission and the range was one to seven days.
Figure 1 shows the diagnostic categories and character-
istics of the 20 IFI patients. Four patients had proven
IFIs, and 3 of these patients had Aspergillus and 1
patient had Candida. Eleven patients had probable IFIs,
and 4 of these patients had Aspergillus, 5 patients had
Candida, and 2 patients had other fungi. Five patients
had possible IFIs, and all 5 patients had Aspergillus.
All 20 patients with IFIs had lung involvement, and two
patients had concurrent central nervous system infection
by Aspergillus. All 60 of the HSCT patients received
empiric treatment with fluconazole if neutropenia was
diagnosed. Aspergillus spp. was the most common isolate
(12 of 20 patients). All patients with proven IFI and pos-
sible IFI died. Only three of the 20 patients with probable
IFI survived, one with probable Aspergillus who was trea-
ted with amphotericin B, and two with probable Candida
who were treated with fluconazole. For the three IFI
patients who survived, one had Aspergillus flavus and the
other two had Candida spp. other than C. tropicalis or C.
albicans. Among the 17 IFI patients who died, the causes
of death were multiple organ failure (12 patients), septic
shock (3 patients), and profound hypoxemia (2 patients).
Discussion
T h em a j o rf i n d i n g so ft h i ss t u d yw e r et h a tH S C T
patients undergoing MV in the ICU had a high inci-
dence of IFI (33%) and high ICU mortality (88%).
Patients with IFIs had a significantly longer duration
from HSCT to ICU admission, higher percentage of
GVHD, and greater use of high-dose corticosteroid use
than patients without IFIs. Although univariate analysis
indicated that IFI patients had lower APACHE II and
SOFA scores, multivariate analysis indicated that these
were not independently associated with IFI. Moreover,
the ICU mortality rate was similar for patients with and
without IFIs.
Several previous studies have reported high mortality
rates in HSCT recipients who were admitted to ICUs. In
particular, Soubani reported that intubated HSCT
patients had an ICU mortality rate of nearly 100% before
1990, but that the mortality rate decreased to 61-67% in
Table 1 Characteristics of HSCT patients with mechanical
ventilation (n = 60)
Mean ± S.D. or Number (%)
a
Age at transplantation, yrs. 34.5 ± 10.3
Gender
Male 37 (61.6%)
Female 23 (38.4%)
Underlying disease
ALL 9 (15%)
AML 14 (23.3%)
Aplastic anemia 2 (3.3%)
CML 12 (20%)
Multiple myeloma 4 (6.7%)
MDS 2 (3.3%)
Hodgkin’s disease 4 (6.7%)
Non Hodgkin’s lymphoma 8 (13.3%)
Other 5 (8.3%)
Type of transplantation
Allo-PBSCT 36 (60%)
Auto-PBSCT 13 (21.7%)
Allo-BMT 10 (16.7%)
Auto-BMT 1 (1.7%)
GVHD
Yes 31
No 15
APACHE II score 24.5 ± 9.4
APACHE II > 25 (Patient number) 27
SOFA score 12 ± 3.7
Duration from HSCT to ICU, days 106.4 ± 99.5
aData represent the mean ± S.D or the number of patients and percentage in
parentheses.
Abbreviations: HSCT: hematopoietic stem cell transplantation; ALL: acute
lymphoid leukemia; AML: acute myeloid leukemia; CML: chronic myeloid
leukemia; MDS: myelodysplastic syndrome; PBSCT: peripheral blood stem cell
transplantation; BMT: bone marrow transplantation; GVHD: graft versus host
disease; APACHE II: acute physiology and chronic health evaluation II; SOFA:
sequential organ failure assessment.
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Invasive fungal infection
(n = 20)
Without invasive fungal infection
(n = 40)
P-value
Median age at ICU admission 30 ± 7.9 37 ± 11.0 0.024 *
Gender
Male 12 (60%) 15 (37.5%) 0.099
Female 8 (40%) 25 (62.5%)
Early vs. late ICU admission after HSCT (day) 209 ± 158.2 73 ± 56.6 0.068
ICU length of stay (day) 10.7 ± 7.6 12.8 ± 14.5 0.533
Underlying disease
ALL 4 (20%) 5 (12.5%)
AML 8 (40%) 7 (17.5%)
CML 3 (15%) 9 (22.5%)
Multiple myeloma 1 (5%) 3 (7.5%)
Hodgkin’s disease 2 (10%) 2 (5%)
Other hematological disease 2 (10%) 14 (34.5%)
Type of transplantation
Allo-PBSCT/Allo-BMT 13 (65%)/4 (20%) 24 (60%)/5 (12.5%)
Auto-PBSCT/Auto-BMT 3 (15%)/0 10 (25%)/1 (2.5%)
GVHD 16 (80%) 15 (37.5%) 0.003 **
CMV infection 7 (35%) 6 (15%) 0.101
Neutropenia 16(80%) 32 (80%) 0.099
Concurrent bacteremia 12 (60%) 26 (65%) 0.705
High dose corticosteroid 13 (65%) 10 (25%) 0.003 *
APACHE II score 22 ± 5.7 27 ± 9.8 0.014 *
SOFA score 10.45 ± 2.7 13 ± 4.0 0.020 *
ICU mortality 17 (85%) 36 (90%) 0.676
*: p < 0.05; **: p < 0.01.
Data represent as mean ± S.D or number (percentage).
Abbreviations: HSCT: hematopoietic stem cell transplantation; ALL: acute lymphoid leukemia; AML: acute myeloid leukemia; CML: chronic myeloid leukemia; MDS:
myelodysplastic syndrome; PBSCT: peripheral blood stem cell transplantation; BMT: bone marrow transplantation; GVHD: graft versus host disease; APACHE II:
acute physiology and chronic health evaluation II; SOFA score: sequential organ failure assessment score; and ICU: intensive care unit.
Table 3 Univariate and multivariate analysis of clinical variables associated with invasive fungal infection
Univariate analysis Multi-variate analysis
Variable Odds Ratio 95% C.I. P-value Odds ratio 95% C.I. P-value
Age > 30 0.333 0.108 - 1.034 0.053
Gender 0.900 0.300 - 2.704 0.099
Late ICU admission (> 40 days after HSCT) 6.500 1.916 - 22.052 0.002 ** 1.003 1.001 - 1.006 0.008 *
Type of transplantation 0.465 0.114 - 1.906 0.281
GVHD 6.667 1.874 - 23.714 0.002 * 8.291 1.687 - 40.746 0.009 *
CMV infection 3.051 0.862 - 10.799 0.101
Neutropenia (ICU admission) 1.000 0.261 - 3.826 0.099
Concurrent bacteremia 0.808 0.267 - 2.440 0.705
High dose corticosteroid use 5.571 1.738 - 17.856 0.003 * 9.459 2.040 - 43.867 0.004 *
APACHE II > 25 0.130 0.033 - 0.518 0.002 *
SOFA > 12 0.250 0.071 - 0.880 0.025 *
ICU Mortality 0.810 0.173 - 3.792 0.676
a. If cells had expected count less than 5, Fisher’s Exact Test was used.
b. *: p < 0.05; **: p < 0.01
Abbreviations: C.I.: confidence interval; HSCT: hematopoietic stem cell transplantation; GVHD: graft versus host disease; CMV: cytomegalovirus; APACHE II: acute
physiology and chronic health evaluation II; SOFA score: sequential organ failure assessment score; ICU: intensive care unit.
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was directly related to the number of organ system fail-
ures and use of MV rather than their status as HSCT
recipients [4,6]. Other research reported that early initia-
tion of noninvasive positive ventilation decreased the
likelihood of invasive endotracheal intubation, and can
improve the survival rate of HSCT patients with respira-
tory failure [5]. The high ICU mortality rate in the pre-
sent study (88%) may be partially explained by the fact
that all enrolled patients were receiving invasive MV
upon ICU admission.
Previous reports indicated that impaired cell-mediated
immunity and use of immunosuppressants to treat
GVHD led to CMV reactivation in HSCT patients
[14,15]. In particular, CMV reactivation was identified
as a significant independent risk factor for HSCT
patients with IFIs during the early post-engraftment
phase [14,15]. The HSCT patients undergoing MV with
IFIs in the present study also had higher percentage of
CMV infection than those without IFIs (7 of 20, 35% vs.
6 of 40, 15%, respectively), although this difference was
not statistically significant.
Previous studies reported that the risk factors for IFI in
HSCT recipients were presence of an underlying disease,
advanced age, donor type, GVHD, and use of corticoster-
oids [16-18]. Moreover, higher grade GVHD and higher
dose of corticosteroid were associated with increased
likelihood of an IFI [19,20]. Other studies reported that
neutropenia and use of immunosuppressants to treat
GVHD were associated with IFI [21,22]. The presence of
neutropenia increases the risk of developing bacterial or
fungal infections. During the neutropenic period, HSCT
patients have increased risk of developing severe sepsis,
septic shock, and multiple organ failure, making it neces-
sary for more intensive care that includes MV. However,
the present study of HSCT patients undergoing MV indi-
cated that significant risk factors for IFI were GVHD and
use of high-dose corticosteroid, but not neutropenia. The
very high overall rate of neutropenia in our severely ill
patients (80%) may partially explain why there was no
significant difference in neutropenia between patients
with and without IFIs.
During our study period, 7 of 326 HSCT patients were
admitted to the ICU without MV. Among these 7 non-
ventilated critically ill patients, 4 patients had IFIs (57%)
and all 4 of these patients were diagnosed with possible
IFI by Aspergillus spp. following ICU admission more
than 40 days after HSCT. Two of these 4 patients died.
Clearly, a larger number of patients are needed to estab-
lish the influence of IFI on the outcome of non-venti-
lated critically ill HSCT patients. A previous study
reported that IFIs in HSCT patients differed according
to the time of infection after HSCT [14]. IFI cases that
occurred within 40 days of HSCT were predominantly
Candida infections and were more common in patients
with active hematological disease, longer duration of
neutropenia, and severe GVHD [6,14]. IFI cases that
occurred more than 40 days after HSCT were predomi-
nantly Aspergillus infections, and were more common in
patients with mismatched related donor transplants,
severe GVHD, and use of high-dose corticosteroid
[6,14]. In the present study, IFI was diagnosed a mean
of 209 days after HSCT, during the late post-engraft-
ment phase. The use of a non-myeloablative condition-
ing regimen and granulocyte-colony stimulation factor
(G-CSF) may improve the transplantation success and
reduce the duration of neutropenia. Furthermore, these
improvements appeared to decrease the incidence of
early IFI, but increase the incidence of late IFI.
The GITMO (Gruppo Italiano Trapianto di Midollo
Osseo) study reported that Aspergillosis accounted for
80% of invasive fungal infections in HSCT patients [23].
I no u rp a t i e n t sw i t hI F I s ,6 0 %( 1 2o f2 0p a t i e n t s )h a d
Aspergillosis, and Aspergillus flavus was the most com-
mon species (3 of 11 patients). In the early 1990s, Can-
dida albicans accounted for about two-thirds of
Candida infections, but this decreased to about 50% by
the end of the last decade [24]. Our results indicated
that Candida albicans was the most isolated species of
Candida (50%, 3 of 6 patients).
HSCT patients who have IFIs have poor prognosis,
and the overall mortality rate of our HSCT patients
undergoing MV was 88%. Our results also indicated
similar ICU mortality rates in patients with and without
IFIs. Thus, the presence of an IFI had no further impact
on the already dismal prognosis of HSCT patients
undergoing MV.
There were three major limitations in our study. First,
we included patients who were diagnosed with “possible
Figure 1 Diagnostic categories and characteristics of patients
with invasive fungal infections.
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probable diagnosis. It is possible that some of these
“possible IFI” patients did not actually have IFIs. If so,
then the differences between the two groups may have
been reduced. Second, our study was retrospective and
was performed at a single tertiary care medical center,
so the findings have limited generalizability. Third, anti-
fungal azoles and echinocandins have only been avail-
able in the last five years at our institute, so other
populations with longer histories of azole and echino-
candin use may have different results.
Conclusion
HSCT patients undergoing MV in the ICU had a high
rate of IFI and had an extremely high rate of mortality.
The risk factors for IFI in HSCT patients undergoing
MV were long time from HCST to ICU admission, pre-
sence of GVHD, and use of high-dose corticosteroid.
Recognition of risk factors for an IFI and early use of
effective antifungal agents that can treat Aspergillus and
fluconazole-resistant Candida spp. may provide better
outcomes for HSCT patients with IFIs.
Key message
￿ Hematopoietic stem cell transplantation (HSCT)
patients undergoing mechanical ventilation (MV) in
the intensive care unit (ICU) had a high rate of inva-
sive fungal infection (IFI) and an extremely high rate
of mortality.
￿ The risk factors for IFI in HSCT patients under-
going MV were late ICU admission after HSCT,
GVHD, and use of high dose corticosteroid.
￿ In our study cohort, Aspergillus was the primary
cause of IFI in and infection mostly occurred during
the late post-engraftment phase.
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